Branford, United States
EvolveImmune Therapeutics, founded in 2020 and headquartered in the United States, is a biotechnology company creating innovative solutions for cancer treatment. Their slogan, "Reimagining Cancer Immunotherapy", reflects their ambitious approach in developing unique trispecific T cell engagers via their proprietary EVOLVE platform.
With their lead drug candidate, EVOLVE104, poised to enter clinical trials in 2025, the company aims to address the critical challenge of cancer cell resistance to existing immunotherapies. Operating primarily in the Biotechnology and Health Care industries, EvolveImmune stands out with its robust scientific pipeline.
In its recent funding round on 16 November 2023, the company secured a substantial $37.40M in venture capital. Notable investors include Elm Street Ventures, Solasta Ventures, Takeda Pharma, Yonjin Venture, and Pfizer. This diverse investor pool underscores the confidence in the company’s potential to revolutionize cancer treatment.
